Matinas BioPharma Hldgs MTNB announces its next round of earnings this Tuesday, August 10. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
Net Income, Earnings, And Earnings Per Share
Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.
Earnings And Revenue
Wall Street analysts see Matinas BioPharma Hldgs reporting a loss of $-0.03 per share on revenue of $30.00 thousand. In the same quarter last year, Matinas BioPharma Hldgs announced EPS of $0.03 on revenue of $0.00.
Why Analyst Estimates And Earnings Surprises Are Important
Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.
If the company were to match the consensus estimate when it reports Tuesday, EPS would have fallen 0%. Sales would be unchanged from the same quarter last year. Matinas BioPharma Hldgs's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Actual | -0.03 | -0.03 | -0.03 | -0.03 |
| Revenue Estimate | 20.00 K | 1.02 M | 20.00 K | 20.00 K |
| Revenue Actual | 33.33 K | 62.50 K | 95.83 K | 0 |
Want Real-Time Earnings Calendar Updates?
Benzinga consistently updates its earnings calendars to stay up-to-date with the latest company earnings reports. Check out the full earnings calendar list updated in real-time by following this link.
Stock Performance
Shares of Matinas BioPharma Hldgs were trading at $0.7781 as of August 06. Over the last 52-week period, shares are down 9.94%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Do not be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 08:00:00 ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
